Drug interactions

As a substrate of the CYP3A4 enzyme, maraviroc has potential interactions with other drugs broken down by this enzyme. When maraviroc is given with CYP3A inhibitors, the dose should be reduced to 150 mg twice daily. These drugs include most protease inhibitors (except for tipranavir/ritonavir), ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin, among others.1 2

Maraviroc dosing must be increased in the presence of a number of drugs due to their effects on its metabolism through the cytochrome p450 system. The 600mg twice-daily dose of maraviroc should be used with all CYP3A inducers (without a CYP3A inhibitor), including efavirenz, rifampicin, carbamazepine, phenobarbital, and phenytoin.

Etravirine (Intelence), a potent inducer of the cytochrome p450 CYP3A4 pathway, has been found to speed up the metabolism of maraviroc enormously and it reduces total maraviroc concentrations over a 12-hour period by 53% (AUC12) and peak levels of maraviroc (Cmax) by 60%. Consequently, if an individual is not also taking a potent CYP3A4 inhibitor, such as a protease inhibitor, the recommended clinical dose for maraviroc alongside etravirine is 600mg twice daily. However, if maraviroc is being dosed alongside etravirine and darunavir together, the 150mg twice-daily dose is sufficient. Co-administration of etravirine/darunavir/ritonavir with maraviroc increased the exposure of maraviroc by 210% (AUC12) and peak levels (Cmax) by 77% compared to maraviroc alone.

These results, where the combination of a potent inducer of CYP mediated metabolism (etravirine) and a potent inhibitor of CYP mediated metabolism (darunavir/ritonavir) yields a net increase in maraviroc concentrations, are consistent with previous inducer/inhibitor combination data, where the net effect appears to be inhibition.

Etravirine pharmacokinetic data showed no effect of maraviroc on etravirine pharmacokinetics. Therefore, no dose adjustment of etravirine is necessary. The dose remains 200mg twice daily. Safety data from the study indicated that co-administration of etravirine and maraviroc was generally safe and well tolerated.

References

  1. Muirhead G et al. An investigation into the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P283, 2004
  2. Abel S et al. An open, randomized, 2-way crossover study to investigate the effects of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects. Eighth International Workshop on Pharmacology of HIV Therapy, Budapest, abstract 55, 2007
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.